Development of a yeast assay for rapid screening of inhibitors of human-derived Pneumocystis carinii dihydrofolate reductase

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 9, 2002, Pages 3101-3103

  Ma, Liang ^a   Jia, Qiuyao ^a   Kovacs, Joseph A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; ANTIFUNGAL AGENT; DIHYDROFOLATE REDUCTASE; PYRIMETHAMINE; TRIMETHOPRIM; TRIMETREXATE;

ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; ENZYME INHIBITION; FUNGUS GROWTH; IC 50; NONHUMAN; PNEUMOCYSTIS CARINII; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE;

EID: 0036720296     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.9.3101-3103.2002     Document Type: Article

References (15)

1. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent
2. Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate
3. Identification of Cryptosporidium parvum dihydrofolate reductase inhibitors by complementation in Saccharomyces cerevisiae
4. Comparison of ternary complexes of Pneumocystis carinii and wild-type human dihydrofolate reductase with coenzyme NADPH and a novel classical antitumor furo[2,3-d]pyrimidine antifolate
5. Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene
6. The phenotype of a dihydrofolate reductase mutant of Saccharomyces cerevisiae
7. Efficacies of lipophilic inhibitors of dihydrofolate reductase against parasitic protozoa
8. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use
9. Genetic divergence of the dihydrofolate reductase and dihydropteroate synthase genes in Pneumocystis carinii from 7 different host species
10. Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase
11. The in vitro activity of experimental antimalarial compounds against strains of Plasmodium falciparum with varying degrees of sensitivity to pyrimethamine and chloroquine, p. 58
12. Activity of PS-15 and its metabolite, WR99210, against Plasmodium falciparum in an in vivo-in vitro model
13. Yeast as a model system to study drugs effective against apicomplexan proteins
14. Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia
15. Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum